Research Advance of Photodynamic Therapy on Cholangiocarcinoma_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 JIANGHai-tao ¹ ,  CAOJing-yu ²

1. Department of General Surgery, Ningbo No. 2 Hospital, Ningbo 315010, Zhejiang Province, China;
2. Department of Hepatobiliary Surgery, The Affiliated Hospital of Qingdao University, Qingdao 266003, Shandong Province, China;

Corresponding?author：

CAOJing-yu, Email: cjy7027@163.com

Keywords：

Photodynamic therapy; Photosensitizer; Cholangiocarcinoma; Apoptosis

DOI：

10.7507/1007-9424.20150165

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To understand the research advance of photodynamic therapy (PDT) on cholangiocarcinoma. Method Domestic and international publications online which involving the research of PDT on cholangiocarcinoma in recent years were reviewed. Results ①PDT was a new therapy on tumor from the tissue and cell level, which could destroy the target tissue and cell under the photochemical reaction and kill the tumor cell according to the characteristics of the selective intake of tumor tissue on particular photosensitizer. It could mainly induce tumor cell apoptosis and necrosis, destroy the tumor microvascular, stimulate the immune and inflammatory response.②PDT on the research level of the treatment of cholangiocarcinoma had achieved fairly good curative effects, which could make the tumor shrinkage, reduce the harm to normal bile duct cell, and prolong the survival, improve the survival rate and the quality of life.③Proliferating cell nuclear antigen (PCNA), vascular endothelial growth factor-C (VEGF-C), and cyclooxygenase-2 (COX-2) played important roles in the development of cholangiocarcinoma. PDT could inhibit the expressions of PCNA, VEGF-C, and COX-2, and then could promote cell apoptosis, and then inhibit cell proliferation. Conclusions PDT is a new technology in treatment of malignant tumor, which whether used alone or combined with other methods has less adverse reaction and could obviously improve the local symptoms in treatment of cholangiocarcinoma. But many problems about PDT need to be solved at present, in the base areas, such as research and development of new photosensitizer and precise mechanism of killing tumor, in the clinical applications, such as selection and application of photosensitizer, ways and parameters of the laser, formulation of treatment plans and the reduction of the complications.

Citation： JIANGHai-tao, CAOJing-yu. Research Advance of Photodynamic Therapy on Cholangiocarcinoma. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2015, 22(5): 633-636. doi: 10.7507/1007-9424.20150165 Copy

1.	Olnes MJ, Erlich R. A review and update on cholangiocarcinoma. Oncology, 2004, 66(3):167-179.
2.	Heimbach JK. Successful liver transplantation for hilar cholangiocarcinoma. Curr Opin Gastroenterol, 2008, 24(3):384-388.
3.	Sagawa N, Kondo S, Morikawa T, et al. Effectiveness of radiation therapy after surgery for hilar cholangiocarcinoma. Surg Today, 2005, 35(7):548-552.
4.	Todoroki T. Chemotherapy for bile duct carcinoma in the light of adjuvant chemotherapy to surgery. Hepatogastroenterology, 2000, 47(33):644-649.
5.	Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer, 2003, 3(5):380-387.
6.	Saikali S, Avril T, Collet B, et al. Expression of nine tumour antigens in a series of human glioblastoma multiforme:interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy. J Neurooncol, 2007, 81(2):139-148.
7.	Nowis D, Stoklosa T, Legat M, et al. The influence of photodynamic therapy on the immune response. Photodiagnosis Photodyn Ther, 2005, 2(4):283-298.
8.	Almeida RD, Manadas BJ, Carvalho AP, et al. Intracellular signaling mechanisms in photodynamic therapy. Biochim Biophys Acta, 2004, 1704(2):59-86.
9.	Buytaert E, Dewaele M, Agostinis P. Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. Biochim Biophys Acta, 2007, 1776(1):86-107.
10.	Huettner CS, Zhang P, Van Etten RA, et al. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet, 2000, 24(1):57-60.
11.	Ferri KF, Kroemer G. Organelle-specific initiation of cell death pathways. Nat Cell Biol, 2001, 3(11):E255-E263.
12.	Castano AP, Demidova TN, Hamblin MR. Mechanisms in photodynamic therapy:Part three-Photosensitizer pharmacokinetics, biodistribution, tumor localization and modes of tumor destruction. Photodiagnosis Photodyn Ther, 2005, 2(2):91-106.
13.	Santonocito C, Concolino P, Lavieri MM, et al. Comparison between three molecular methods for detection of blood melanoma tyrosinase mRNA. Correlation with melanoma stages and S100B, LDH, NSE biochemical markers. Clin Chim Acta, 2005, 362(1-2):85-93.
14.	Roland CL, Harken AH, Sarr MG. ICAM-1 expression determines malignant potential of cancer. Surgery, 2007, 141(6):705-707.
15.	Korbelik M, Sun J, Zeng H. Ischaemia-reperfusion injury in photodynamic therapy-treated mouse tumours. Br J Cancer, 2003, 88(5):760-766.
16.	Curnow A, Bown SG. The role of reperfusion injury in photodynamic therapy with 5-aminolaevulinic acid-a study on normal rat colon. Br J Cancer, 2002, 86(6):989-992.
17.	Riedemann NC, Ward PA. Complement in ischemia reperfusion injury. Am J Pathol, 2003, 162(2):363-367.
18.	Haqq C, Nosrati M, Sudilovsky D, et al. The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A, 2005, 102(17):6092-6097.
19.	Shaib YH, Davila JA, McGlynn K, et al. Rising incidence of intrahepatic cholangiocarcinoma in the United States:a true increase? J Hepatol, 2004, 40(3):472-477.
20.	Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metasis Rev, 2000, 19(1-2):19-27.
21.	Tamura M, Sebastian S, Gurates B, et al. Vascular endothelial growth factor up-regulates cyclooxygenase-2 expression in human endothelial. J Clin Endocrinol Metab, 2002, 87(7):3504-3507.
22.	梁平, 陳海, 莊大勇, 等. PCNA和bcl-2在金倉鼠膽管癌和膽管細胞增生中的表達.第三軍醫大學學報, 2001, 23(7):790-792.
23.	肖科, 湯恢煥.血管內皮生長因子C和微淋巴管密度與膽管癌淋巴結轉移及預后的關系.中國普通外科雜志, 2012, 21(8):946-951.
24.	Chariyalertsak S, Sirikulchayanonta V, Mayer D, et al. Aberrant cyclooxygenase isozyme expression in human intrahepatic cholangiocarcinoma. Gut, 2001, 48(1):80-86.
25.	姜海濤, 曹景玉, 韓瑞, 等.光動力療法促進膽管癌細胞QBC939的凋亡.世界華人消化雜志, 2013, 21(19):1853-1858.
26.	Jiang HT, Cao JY, Han R. The influence of photodynamic therapy on human cholangiocarcinoma QBC939 cell line apoptosis and invasion. Jokull J, 2013, 63(11):56-65.
27.	姜海濤, 曹景玉, 吳力群, 等.光動力療法對人膽管癌細胞QBC939凋亡的影響.中華肝膽外科雜志, 2013, 19(6):456-460.
28.	韓瑞, 曹景玉, 姜海濤, 等.血卟啉光動力對人膽管癌細胞轉移潛能影響實驗研究.中華腫瘤防治雜志, 2014, 21(2):113-117.
29.	Maga G, Hübscher U. Proliferating cell nuclear antigen (PCNA):a dancer with many partners. J Cell Sci, 2003, 116(Pt 15):3051-3060.
30.	Park J H, Ahn M Y, Kim Y C, et al. In vitro and in vivo antimicrobial effect of photodynamic therapy using a highly pure chlorin e(6) against staphylococcus aureus Xen29. Biol Pharm Bull, 2012, 35(4):509-514.
31.	Li P, Zhou G, Zhu X, et al. Photodynamic therapy with hyperbranched poly (ether-ester) chlorin (e6) nanoparticles on human tongue carcinoma CAL-27 cells. Photodiagnosis Photodyn Ther, 2012, 9(1):76-82.
32.	Kasuya K, Shimazu M, Suzuki M, et al. Novel photodynamic therapy against biliary tract carcinoma using mono-l-aspartyl chlorine e6:basic evaluation for its feasibility and efficacy. J Hepatobiliary Pancreat Sci, 2010, 17(3):313-321.
33.	邵志堅, 薛平, 盧海武, 等.光動力治療人膽管癌細胞荷瘤裸鼠的實驗研究.肝膽胰外科雜志, 2007, 19(5):285-287, 303.
34.	Kahaleh M, Mishra R, Shami VM, et al. Unresectable cholangiocarcinoma:comparison of survival in biliary stenting alone versus stenting with photodynamic therapy. Clin Gastroenterol Hepatol, 2008, 6(3):290-297.
35.	Ortner ME, Caca K, Berr F, et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma:A randomized prospective study. Gastroenterology, 2003, 125(5):1355-1363.
36.	Quyn AJ, Ziyaie D, Polignano FM, et al. Photodynamic therapy is associated with an improvement in survival in patients with irresectable hilar cholangiocarcinoma. HPB (Oxford), 2009, 11(7):570-577.
37.	Zoepf T, Jakobs R, Arnold JC, et al. Palliation of nonresectable bile duct cancer:improved survival after photodynamic therapy. Am J Gastroenterol, 2005, 100(11):2426-2430.
38.	Gerhardt T, Rings D, Hoeblinger A, et al. Combination of bilateral metal stenting and trans-stent photodynamic therapy for palliative treatment of hilar cholangiocarcinoma. Z Gastroenterol, 2010, 48(1):28-32.
39.	Cheon YK, Lee TY, Lee SM, et al. Longterm outcome of photodynamic therapy compared with biliary stenting alone in patients with advanced hilar cholangiocarcinoma. HPB (Oxford), 2012, 14(3):185-193.
40.	任延剛, 郭啟勇, 盧再鳴.光動力療法治療膽管癌的系統評價.中國循證醫學雜志, 2007, 7(6):456-460.
41.	Fuks D, Bartoli E, Delcenserie R, et al. Biliary drainage, photodynamic therapy and chemotherapy for unresanectable cholangiocarcinoma with jaundice. J Gastroenterol Hepatol, 2009, 24(11):1745-1752.
42.	Witzigmann H, Berr F, Ringel U, et al. Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma:palliative photodynamic therapy plus stenting is comparable to R1/R2 resection. Ann Surg, 2006, 244(2):230-239.
43.	Nanashima A, Yamaguchi H, Shibasaki S, et al. Adjuvant photodynamic therapy for bile duct carcinoma after surgery:a preliminary study. J Gastroenterol, 2004, 39(11):1095-1101.

1. Olnes MJ, Erlich R. A review and update on cholangiocarcinoma. Oncology, 2004, 66(3):167-179.
2. Heimbach JK. Successful liver transplantation for hilar cholangiocarcinoma. Curr Opin Gastroenterol, 2008, 24(3):384-388.
3. Sagawa N, Kondo S, Morikawa T, et al. Effectiveness of radiation therapy after surgery for hilar cholangiocarcinoma. Surg Today, 2005, 35(7):548-552.
4. Todoroki T. Chemotherapy for bile duct carcinoma in the light of adjuvant chemotherapy to surgery. Hepatogastroenterology, 2000, 47(33):644-649.
5. Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer, 2003, 3(5):380-387.
6. Saikali S, Avril T, Collet B, et al. Expression of nine tumour antigens in a series of human glioblastoma multiforme:interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy. J Neurooncol, 2007, 81(2):139-148.
7. Nowis D, Stoklosa T, Legat M, et al. The influence of photodynamic therapy on the immune response. Photodiagnosis Photodyn Ther, 2005, 2(4):283-298.
8. Almeida RD, Manadas BJ, Carvalho AP, et al. Intracellular signaling mechanisms in photodynamic therapy. Biochim Biophys Acta, 2004, 1704(2):59-86.
9. Buytaert E, Dewaele M, Agostinis P. Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. Biochim Biophys Acta, 2007, 1776(1):86-107.
10. Huettner CS, Zhang P, Van Etten RA, et al. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet, 2000, 24(1):57-60.
11. Ferri KF, Kroemer G. Organelle-specific initiation of cell death pathways. Nat Cell Biol, 2001, 3(11):E255-E263.
12. Castano AP, Demidova TN, Hamblin MR. Mechanisms in photodynamic therapy:Part three-Photosensitizer pharmacokinetics, biodistribution, tumor localization and modes of tumor destruction. Photodiagnosis Photodyn Ther, 2005, 2(2):91-106.
13. Santonocito C, Concolino P, Lavieri MM, et al. Comparison between three molecular methods for detection of blood melanoma tyrosinase mRNA. Correlation with melanoma stages and S100B, LDH, NSE biochemical markers. Clin Chim Acta, 2005, 362(1-2):85-93.
14. Roland CL, Harken AH, Sarr MG. ICAM-1 expression determines malignant potential of cancer. Surgery, 2007, 141(6):705-707.
15. Korbelik M, Sun J, Zeng H. Ischaemia-reperfusion injury in photodynamic therapy-treated mouse tumours. Br J Cancer, 2003, 88(5):760-766.
16. Curnow A, Bown SG. The role of reperfusion injury in photodynamic therapy with 5-aminolaevulinic acid-a study on normal rat colon. Br J Cancer, 2002, 86(6):989-992.
17. Riedemann NC, Ward PA. Complement in ischemia reperfusion injury. Am J Pathol, 2003, 162(2):363-367.
18. Haqq C, Nosrati M, Sudilovsky D, et al. The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A, 2005, 102(17):6092-6097.
19. Shaib YH, Davila JA, McGlynn K, et al. Rising incidence of intrahepatic cholangiocarcinoma in the United States:a true increase? J Hepatol, 2004, 40(3):472-477.
20. Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metasis Rev, 2000, 19(1-2):19-27.
21. Tamura M, Sebastian S, Gurates B, et al. Vascular endothelial growth factor up-regulates cyclooxygenase-2 expression in human endothelial. J Clin Endocrinol Metab, 2002, 87(7):3504-3507.
22. 梁平, 陳海, 莊大勇, 等. PCNA和bcl-2在金倉鼠膽管癌和膽管細胞增生中的表達.第三軍醫大學學報, 2001, 23(7):790-792.
23. 肖科, 湯恢煥.血管內皮生長因子C和微淋巴管密度與膽管癌淋巴結轉移及預后的關系.中國普通外科雜志, 2012, 21(8):946-951.
24. Chariyalertsak S, Sirikulchayanonta V, Mayer D, et al. Aberrant cyclooxygenase isozyme expression in human intrahepatic cholangiocarcinoma. Gut, 2001, 48(1):80-86.
25. 姜海濤, 曹景玉, 韓瑞, 等.光動力療法促進膽管癌細胞QBC939的凋亡.世界華人消化雜志, 2013, 21(19):1853-1858.
26. Jiang HT, Cao JY, Han R. The influence of photodynamic therapy on human cholangiocarcinoma QBC939 cell line apoptosis and invasion. Jokull J, 2013, 63(11):56-65.
27. 姜海濤, 曹景玉, 吳力群, 等.光動力療法對人膽管癌細胞QBC939凋亡的影響.中華肝膽外科雜志, 2013, 19(6):456-460.
28. 韓瑞, 曹景玉, 姜海濤, 等.血卟啉光動力對人膽管癌細胞轉移潛能影響實驗研究.中華腫瘤防治雜志, 2014, 21(2):113-117.
29. Maga G, Hübscher U. Proliferating cell nuclear antigen (PCNA):a dancer with many partners. J Cell Sci, 2003, 116(Pt 15):3051-3060.
30. Park J H, Ahn M Y, Kim Y C, et al. In vitro and in vivo antimicrobial effect of photodynamic therapy using a highly pure chlorin e(6) against staphylococcus aureus Xen29. Biol Pharm Bull, 2012, 35(4):509-514.
31. Li P, Zhou G, Zhu X, et al. Photodynamic therapy with hyperbranched poly (ether-ester) chlorin (e6) nanoparticles on human tongue carcinoma CAL-27 cells. Photodiagnosis Photodyn Ther, 2012, 9(1):76-82.
32. Kasuya K, Shimazu M, Suzuki M, et al. Novel photodynamic therapy against biliary tract carcinoma using mono-l-aspartyl chlorine e6:basic evaluation for its feasibility and efficacy. J Hepatobiliary Pancreat Sci, 2010, 17(3):313-321.
33. 邵志堅, 薛平, 盧海武, 等.光動力治療人膽管癌細胞荷瘤裸鼠的實驗研究.肝膽胰外科雜志, 2007, 19(5):285-287, 303.
34. Kahaleh M, Mishra R, Shami VM, et al. Unresectable cholangiocarcinoma:comparison of survival in biliary stenting alone versus stenting with photodynamic therapy. Clin Gastroenterol Hepatol, 2008, 6(3):290-297.
35. Ortner ME, Caca K, Berr F, et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma:A randomized prospective study. Gastroenterology, 2003, 125(5):1355-1363.
36. Quyn AJ, Ziyaie D, Polignano FM, et al. Photodynamic therapy is associated with an improvement in survival in patients with irresectable hilar cholangiocarcinoma. HPB (Oxford), 2009, 11(7):570-577.
37. Zoepf T, Jakobs R, Arnold JC, et al. Palliation of nonresectable bile duct cancer:improved survival after photodynamic therapy. Am J Gastroenterol, 2005, 100(11):2426-2430.
38. Gerhardt T, Rings D, Hoeblinger A, et al. Combination of bilateral metal stenting and trans-stent photodynamic therapy for palliative treatment of hilar cholangiocarcinoma. Z Gastroenterol, 2010, 48(1):28-32.
39. Cheon YK, Lee TY, Lee SM, et al. Longterm outcome of photodynamic therapy compared with biliary stenting alone in patients with advanced hilar cholangiocarcinoma. HPB (Oxford), 2012, 14(3):185-193.
40. 任延剛, 郭啟勇, 盧再鳴.光動力療法治療膽管癌的系統評價.中國循證醫學雜志, 2007, 7(6):456-460.
41. Fuks D, Bartoli E, Delcenserie R, et al. Biliary drainage, photodynamic therapy and chemotherapy for unresanectable cholangiocarcinoma with jaundice. J Gastroenterol Hepatol, 2009, 24(11):1745-1752.
42. Witzigmann H, Berr F, Ringel U, et al. Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma:palliative photodynamic therapy plus stenting is comparable to R1/R2 resection. Ann Surg, 2006, 244(2):230-239.
43. Nanashima A, Yamaguchi H, Shibasaki S, et al. Adjuvant photodynamic therapy for bile duct carcinoma after surgery:a preliminary study. J Gastroenterol, 2004, 39(11):1095-1101.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Research Advance of Photodynamic Therapy on Cholangiocarcinoma

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content